| 1.26 0.05 (4.13%) | 07-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.51  |
1-year : | 1.63 |
| Resists | First : | 1.29 |
Second : | 1.39 |
| Pivot price | 1.2  |
|||
| Supports | First : | 1.12 | Second : | 0.94 |
| MAs | MA(5) : | 1.22 |
MA(20) : | 1.22 |
| MA(100) : | 1.38 |
MA(250) : | 1.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 51.4 |
D(3) : | 43.5 |
| RSI | RSI(14): 51.3 |
|||
| 52-week | High : | 3.95 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MGX ] has closed below upper band by 6.5%. Bollinger Bands are 45.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.27 - 1.28 | 1.28 - 1.28 |
| Low: | 1.16 - 1.17 | 1.17 - 1.17 |
| Close: | 1.25 - 1.26 | 1.26 - 1.27 |
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Thu, 11 Jun 2026
Metagenomi Therapeutics (MGX) director awarded 17,400 stock options at $1.23 - Stock Titan
Thu, 11 Jun 2026
Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strike - Stock Titan
Wed, 10 Jun 2026
Metagenomi CEO Jian Irish sells $4,854 in company stock - Investing.com
Wed, 10 Jun 2026
Metagenomi general counsel Wein sells $724 in common stock - Investing.com
Wed, 10 Jun 2026
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock - Investing.com
Mon, 20 Oct 2025
Here's Why Metagenomi (MGX) is a Great Momentum Stock to Buy - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 2.733e+007 (%) |
| Held by Institutions | 18.9 (%) |
| Shares Short | 1,810 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.755e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 970.1 % |
| Return on Equity (ttm) | -23.5 % |
| Qtrly Rev. Growth | 2.233e+007 % |
| Gross Profit (p.s.) | -107.39 |
| Sales Per Share | -75.42 |
| EBITDA (p.s.) | -1.10292e+008 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.22 |
| Dividend | 0 |
| Forward Dividend | 1.76e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|